Pooja Ghatalia
Fox Chase Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Pooja Ghatalia as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07908979 · Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerFox Chase Cancer Center · recruiting · Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma · principal investigator
- Ph2NCT07221942 · Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial CarcinomaFox Chase Cancer Center · recruiting · Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial Carcinoma · principal investigator
- Ph2NCT05923190 · Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial CarcinomaFox Chase Cancer Center · active not recruiting · Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma · principal investigator
- Ph2NCT04506554 · A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder CancerFox Chase Cancer Center · active not recruiting · Muscle-Invasive Bladder Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:10 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.N Engl J Med · 2024176 citationsRCR 20.7
- Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).J Clin Oncol · 202582 citationsRCR 19.3
- A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.Clin Cancer Res · 202333 citationsRCR 2.4
- A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1).Prostate Cancer Prostatic Dis · 202219 citationsRCR 1.4
- Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.Ann Oncol · 202416 citationsRCR 1.6
- 12 citationsRCR 2.6